Ph 3 Study of Nivo + Relatlimab w/ Chemo vs Pembro w/Chemo FL NSQ NSCLC PD-L1
Phase III Clinical Trial
A Phase 3 Randomized Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ) Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 Expression ≥ 1% (CA2241093)